История
июль 1, 2026

FDA Approves New Sunscreen Ingredient Bemotrizinol

The U.S. Food and Drug Administration (FDA) has approved bemotrizinol, the first new sunscreen ingredient to be allowed in the U.S. in over 25 years. The ingredient, already widely used in Europe, offers enhanced protection against both UVA and UVB rays.

The United States has finally approved bemotrizinol as a sunscreen ingredient, closing a decades‑long gap with Europe—but the milestone also underscores how slowly U.S. regulators have modernized basic consumer health protections.

A long-delayed upgrade

The FDA’s decision marks the first time in more than 25 years that a new sunscreen ingredient has been cleared for the U.S. market. Bemotrizinol has “been in use in Europe for years,” as CBS noted in its initial coverage, highlighting how American consumers have lagged behind other regions in access to newer UV filters.

The newly approved chemical, to be sold first by DSM Nutritional Products under the brand name Parsol Shield, met the agency’s standards for blocking dangerous ultraviolet rays while causing “little irritation or absorption into the skin” and is deemed safe for adults and children over six months old. Experts say it offers broad protection against both UVA and UVB rays without the white cast associated with mineral sunscreens and is less easily broken down by sunlight, meaning longer‑lasting protection.

Regulatory reform vs. regulatory failure

Health and Human Services Secretary Robert F. Kennedy framed the decision as proof that recent reforms are working, praising the move for “advancing innovation” and “increas[ing] competition and consumer confidence in sunscreen products.” Bemotrizinol is the first ingredient to clear a new streamlined process authorized by Congress in 2020, suggesting some bipartisan appetite to unclog what had become a notorious regulatory bottleneck.

Public‑health advocates, however, stress the cost of the delay. Efforts to introduce new sunscreens have been “bogged down for decades by the FDA’s bureaucratic system” for updating over‑the‑counter drug ingredients, CBS reports. David Andrews of the Environmental Working Group is blunter: “For decades, Americans have used outdated sunscreen tech while the rest of the world moved forward.”

The approval of bemotrizinol therefore reads two ways: as a long‑overdue win for consumers and innovation, and as an indictment of a system that needed an act of Congress to deliver a single modern sunscreen filter.